HRP20211492T1 - Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja - Google Patents
Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja Download PDFInfo
- Publication number
- HRP20211492T1 HRP20211492T1 HRP20211492TT HRP20211492T HRP20211492T1 HR P20211492 T1 HRP20211492 T1 HR P20211492T1 HR P20211492T T HRP20211492T T HR P20211492TT HR P20211492 T HRP20211492 T HR P20211492T HR P20211492 T1 HRP20211492 T1 HR P20211492T1
- Authority
- HR
- Croatia
- Prior art keywords
- liraglutide
- intended
- accordance
- approximately
- cardiovascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158739 | 2016-03-04 | ||
| EP16173917 | 2016-06-10 | ||
| EP16001329 | 2016-06-13 | ||
| US15/401,651 US9968659B2 (en) | 2016-03-04 | 2017-01-09 | Liraglutide in cardiovascular conditions |
| PCT/EP2017/054990 WO2017149112A1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
| EP17710160.7A EP3423082B1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211492T1 true HRP20211492T1 (hr) | 2021-12-24 |
Family
ID=59723004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211492TT HRP20211492T1 (hr) | 2016-03-04 | 2017-03-03 | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968659B2 (enExample) |
| EP (1) | EP3423082B1 (enExample) |
| JP (1) | JP6940512B2 (enExample) |
| KR (1) | KR102417455B1 (enExample) |
| CN (2) | CN108778317A (enExample) |
| AU (2) | AU2017225841A1 (enExample) |
| BR (1) | BR112018067344A2 (enExample) |
| CA (1) | CA3013532C (enExample) |
| CL (1) | CL2018002515A1 (enExample) |
| DK (1) | DK3423082T5 (enExample) |
| ES (1) | ES2893755T3 (enExample) |
| HR (1) | HRP20211492T1 (enExample) |
| HU (1) | HUE055844T2 (enExample) |
| IL (1) | IL261169B (enExample) |
| MA (1) | MA43704A (enExample) |
| MX (1) | MX394179B (enExample) |
| MY (1) | MY195657A (enExample) |
| PH (1) | PH12018501844B1 (enExample) |
| PL (1) | PL3423082T3 (enExample) |
| RS (1) | RS62501B1 (enExample) |
| RU (1) | RU2745604C2 (enExample) |
| SI (1) | SI3423082T1 (enExample) |
| WO (1) | WO2017149112A1 (enExample) |
| ZA (1) | ZA201805538B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| CA3177693A1 (en) | 2019-04-05 | 2020-10-05 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| CN118987224A (zh) * | 2020-12-16 | 2024-11-22 | 香港中文大学 | 一种治疗受试者的衰老相关脑功能障碍的组合物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808203A (en) | 1997-05-12 | 1998-09-15 | Medrad, Inc. | Fluid pressure measurement devices |
| JP2005535569A (ja) * | 2002-04-04 | 2005-11-24 | ノボ・ノルデイスク・エー／エス | Ｇｌｐ−１アゴニスト及び心臓血管合併症 |
| CN104826116A (zh) * | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| CN112618700A (zh) * | 2004-11-12 | 2021-04-09 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| WO2009030738A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| JP2016510795A (ja) | 2013-03-15 | 2016-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| JP6507154B2 (ja) | 2013-06-14 | 2019-04-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及びその合併症を治療するためのｄｄｐ−４阻害薬 |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
-
2017
- 2017-01-09 US US15/401,651 patent/US9968659B2/en active Active
- 2017-03-03 AU AU2017225841A patent/AU2017225841A1/en not_active Abandoned
- 2017-03-03 KR KR1020187026962A patent/KR102417455B1/ko active Active
- 2017-03-03 MA MA043704A patent/MA43704A/fr unknown
- 2017-03-03 WO PCT/EP2017/054990 patent/WO2017149112A1/en not_active Ceased
- 2017-03-03 HU HUE17710160A patent/HUE055844T2/hu unknown
- 2017-03-03 CN CN201780015266.5A patent/CN108778317A/zh active Pending
- 2017-03-03 CN CN202310320736.6A patent/CN116327897A/zh active Pending
- 2017-03-03 PL PL17710160T patent/PL3423082T3/pl unknown
- 2017-03-03 ES ES17710160T patent/ES2893755T3/es active Active
- 2017-03-03 HR HRP20211492TT patent/HRP20211492T1/hr unknown
- 2017-03-03 CA CA3013532A patent/CA3013532C/en not_active Expired - Fee Related
- 2017-03-03 MY MYPI2018702782A patent/MY195657A/en unknown
- 2017-03-03 EP EP17710160.7A patent/EP3423082B1/en active Active
- 2017-03-03 BR BR112018067344A patent/BR112018067344A2/pt unknown
- 2017-03-03 PH PH1/2018/501844A patent/PH12018501844B1/en unknown
- 2017-03-03 MX MX2018010097A patent/MX394179B/es unknown
- 2017-03-03 SI SI201730917T patent/SI3423082T1/sl unknown
- 2017-03-03 RS RS20211250A patent/RS62501B1/sr unknown
- 2017-03-03 DK DK17710160.7T patent/DK3423082T5/da active
- 2017-03-03 RU RU2018134061A patent/RU2745604C2/ru active
- 2017-03-03 JP JP2018546477A patent/JP6940512B2/ja active Active
-
2018
- 2018-04-18 US US15/956,445 patent/US20180236038A1/en not_active Abandoned
- 2018-08-15 IL IL26116918A patent/IL261169B/en unknown
- 2018-08-20 ZA ZA2018/05538A patent/ZA201805538B/en unknown
- 2018-09-03 CL CL2018002515A patent/CL2018002515A1/es unknown
-
2024
- 2024-03-26 AU AU2024201937A patent/AU2024201937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| ES2543383T3 (es) | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano | |
| ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| ES2462117T3 (es) | Métodos y composiciones para la administración oral de proteínas | |
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| JP2015038135A5 (enExample) | ||
| AR052198A1 (es) | Formulaciones anticuerpo anti a beta | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| HRP20110444T1 (hr) | Formulacije paratiroidnih hormona i njihove uporabe | |
| RU2018119295A (ru) | Фармацевтические составы для местного применения для лечения связанных с воспалением состояний | |
| BRPI0213425B8 (pt) | composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| CO2019008053A2 (es) | Agente terapéutico para enfermedades del hígado | |
| HRP20250278T1 (hr) | Puferovane formulacije eksendina (9-39) | |
| HRP20211492T1 (hr) | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| HRP20250628T1 (hr) | Mješavine antitijela i postupci njihove upotrebe | |
| HRP20221150T1 (hr) | Semaglutid u kardiovaskularnim stanjima | |
| CO6260085A2 (es) | Composicion farmaceutica que contiene una combinacion sinergica de venotonicos y vasoprotectores | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| HRP20241052T1 (hr) | Semaglutid, namijenjen liječenju alzheimerove demencije |